within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC09_Epoprostenol;

model Epoprostenol
  extends Pharmacolibrary.Drugs.ATC.B.B01AC09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B01AC09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Epoprostenol is a synthetic analog of prostacyclin (PGI2), a potent vasodilator and inhibitor of platelet aggregation, primarily used for the treatment of pulmonary arterial hypertension (PAH). It is approved for intravenous administration in patients with severe PAH to improve exercise capacity and symptoms.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers and patients with pulmonary arterial hypertension after intravenous infusion.</p><h4>References</h4><ol><li><p>Chin, K, &amp; Channick, R (2004). Bosentan. <i>Expert review of cardiovascular therapy</i> 2(2) 175–182. DOI:<a href=&quot;https://doi.org/10.1586/14779072.2.2.175&quot;>10.1586/14779072.2.2.175</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15151466/&quot;>https://pubmed.ncbi.nlm.nih.gov/15151466</a></p></li><li><p>Chaumais, MC, et al., &amp; Montani, D (2010). Pharmacokinetic evaluation of continuous intravenous epoprostenol. <i>Expert opinion on drug metabolism &amp; toxicology</i> 6(12) 1587–1598. DOI:<a href=&quot;https://doi.org/10.1517/17425255.2010.534458&quot;>10.1517/17425255.2010.534458</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21077785/&quot;>https://pubmed.ncbi.nlm.nih.gov/21077785</a></p></li><li><p>Hall, K, et al., &amp; Feinstein, JA (2019). Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease. <i>Journal of cardiovascular pharmacology</i> 73(6) 383–393. DOI:<a href=&quot;https://doi.org/10.1097/FJC.0000000000000674&quot;>10.1097/FJC.0000000000000674</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31162247/&quot;>https://pubmed.ncbi.nlm.nih.gov/31162247</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Epoprostenol;
